Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Non-Current Deferred Tax Liability (2017 - 2025)

Avalo Therapeutics' Non-Current Deferred Tax Liability history spans 9 years, with the latest figure at $434000.0 for Q4 2025.

  • For Q4 2025, Non-Current Deferred Tax Liability fell 69.65% year-over-year to $434000.0; the TTM value through Dec 2025 reached $434000.0, down 69.65%, while the annual FY2025 figure was $434000.0, 69.65% down from the prior year.
  • Non-Current Deferred Tax Liability reached $434000.0 in Q4 2025 per AVTX's latest filing, up from $304000.0 in the prior quarter.
  • In the past five years, Non-Current Deferred Tax Liability ranged from a high of $1.4 million in Q4 2024 to a low of $111000.0 in Q1 2021.
  • Average Non-Current Deferred Tax Liability over 5 years is $242300.0, with a median of $154500.0 recorded in 2023.
  • Peak YoY movement for Non-Current Deferred Tax Liability: surged 822.58% in 2024, then plummeted 69.65% in 2025.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $113000.0 in 2021, then grew by 24.78% to $141000.0 in 2022, then increased by 9.93% to $155000.0 in 2023, then soared by 822.58% to $1.4 million in 2024, then tumbled by 69.65% to $434000.0 in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Non-Current Deferred Tax Liability are $434000.0 (Q4 2025), $304000.0 (Q3 2025), and $293000.0 (Q2 2025).